drugset
drugset / Trial / NCT03631368

Treatment of Hypertrophic Scars With Intradermal Botox

NCT03631368 ↗

Phase 2 Unknown 20 enrolled Roy G. Geronemus, M.D. Allergan · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open label, single center, self-controlled clinical study to demonstrate the safety and efficacy of intradermal botulinum toxin in treating hypertrophic scarring.

Timeline

Start
2018-10-01
Primary completion
2019-05-31
Completion
2019-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — Other

Indications

No indication recorded.